Chronic Kidney Disease

Positive drug trial results suggest promising outcomes for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Exome sequencing of patients with kidney disease and their families identified 17 different monogenetic causes of kidney disease.

A new study says that treating iron deficiency therapy may improve outcomes in patients with chronic kidney disease, even if they don’t have anemia.

Considerable evidence shows sodium-glucose co-transporter-2 inhibitors have cardioprotective benefits, but new research elucidates the ways in which the drugs can also have positive renal impacts.

The proposed changes to the payment model for end stage renal disease (ESRD) would make it the first payment model under the CMS Innovation Center to directly address health equity by incentivizing increased rates of home dialysis and kidney transplants.

The math is straightforward: The best way for employers and insurers to avoid paying for dialysis is to invest in preventive care.

How therapeutic advances can address all 3 conditions was the topic of a symposium Friday during the 81st Scientific Sessions of the American Diabetes Association (ADA), “The Intersection of Diabetes, Heart Failure and Kidney Disease: Challenges and New Insights.”

Adults with normal kidney function who have comorbid depression are more likely to experience a decline in kidney function and have mental and physical impairments from that decline.

Eligible patients who are not waitlisted for kidney transplants lose profound opportunities and are subject to racial and socioeconomic disparities regarding waitlist placement, a study showed.

Dapagliflozin substantially slowed the progression of chronic kidney disease (CKD) in patients with immunoglobulin A nephropathy, according to a new study.

Older patients with chronic kidney disease face higher risks of intensive care unit admission and in-hospital mortality if they contract COVID-19, a new report shows.

The founder of the Renal Support Network discusses why patients with chronic kidney disease want Congress to change Medicare policy to allow payment for oral treatments for anemia caused by iron deficiency.

About 5.4% of patients with end-stage renal disease (ESRD) who begin renal replacement therapy as children go on to have vascular events, and 4.1% of those patients die as a result of vascular events, though the real incidence rates are likely higher, according to new research.

A new analysis reveals penalties levied under a CMS program to improve the quality of care at dialysis centers did not lead to significant change.

Some consider patients with type 2 diabetes (T2D) and chronic kidney disease poor candidates for metformin monotherapy due to the risk of lactic acidosis. However, new research finds patients who can tolerate the drug can gain similar benefits with or without kidney disease.

Closing out the discussion, an expert in chronic kidney disease (CKD) highlights how care for patients with CKD may change in the future based on data presented at AMCP.

Robert Toto, MD, provides his expert opinion regarding recent data from Forsythe, et al about the clinical and humanistic burden of IgA nephropathy.

An expert in chronic kidney disease (CKD) provides a recap of data, recently released at AMCP, around the estimate of the US incident population of IgA nephropathy.

The new analysis suggests that dementia screenings might also include kidney function estimation.

An overview of the implications of the recent dapagliflozin data in chronic kidney disease (CKD) treatment to US clinicians and payers.

An expert in chronic kidney disease (CKD) discusses the importance of showing data at the 3-year mark for the DAPA-CKD study, released at AMCP.

Robert Toto, MD, recaps another recent analysis of data from DAPA-CKD that looked at the time-to-event and cost consequence of delaying clinical events in chronic kidney disease (CKD).

Two-thirds of patients with diabetic kidney disease who are eligible for treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors are not being prescribed them, a new study shows.

Sodium-glucose transporter 2 (SGLT2) inhibitors decrease the risk of acute kidney injury and severe hypoglycemia for those with diabetes, heart failure, and chronic kidney disease (CKD) but increase the risk of diabetic ketoacidosis.

A recap of the dapagliflozin data from the DAPA-CKD study and how it relates to reductions in healthcare resource utilization.